作为绿色载体的β-环氧金属有机框架,可改善氨酸的溶解,生物可用性和肝脏保护作用
Dan Yang1,2, Min Zhao1, Yihe Huang3
1School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, Liaoning Province, China.
International journal of pharmaceutics: X
|May 7, 2024
概括
循环德克斯金属有机框架 (CD-MOFs) 增强了氨酸的作用.
科学领域:
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 乙氨基诱导的肝损伤是有限的预防策略越来越令人担忧.
- 氨酸表现出肝脏保护性质,但具有较差的溶解性和生物利用性.
- 环氧金属有机框架 (CD-MOF) 由于其多孔结构,为药物输送提供了一个有前途的解决方案.
研究的目的:
- 利用CD-MOF来增强黄素的溶解,抗氧化活性,生物可用性和肝脏保护作用.
- 调查含有黄素的CD-MOF作为预防乙氨基引起的肝损伤的新方法.
主要方法:
- 素被装入各种CD-MOF (β-CD-MOF, γ-CD-MOF) 和环极 (β-CD, γ-CD) 中.
- 描述涉及粉末X射线衍光测量 (PXRD) 和热重力测量分析 (TGA).
- 用分子模拟来确定相互作用力. 在体外和体内研究中评估了溶解,抗氧化活性,生物可用性和肝脏保护作用.
主要成果:
- 氨酸-β-CD-MOF表现出优越的稳定性和高负载能力 (14.67%).
- 与原始白莲相比,白莲-β-CD-MOF的溶解率增加了4.5倍,并且在体外增强了抗氧化活性.
- 在体内研究显示,氨酸的生物可用性显著增加 (在健康大鼠中是4.04倍,在乙胺诱导的肝损伤模型中是11.07倍).
结论:
- 氨酸-β-CD-MOF有效地提高了氨酸的溶解性,生物可用性和抗氧化能力.
- 氨酸-β-CD-MOF在体内表现出对乙氨基诱导的肝损伤具有优越的肝保护作用.
- 这项研究将CD-MOF作为一种可行的策略,用于开发用于保护肝脏的新疗法.
相关概念视频
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
200
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
200
00:56Extraction: Advanced Methods
446
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
446
01:17Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
01:14Hepatic Drug Clearance: Role of Transporters
54
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
54
01:16Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K